2. Immunology/Inflammation Apoptosis MAPK/ERK Pathway
  3. MHC Apoptosis JNK
  4. 1D09C3

1D09C3 是一种全人源化的抗 HLA-DR 单克隆抗体。1D09C3 通过一系列级联反应诱导细胞凋亡 (apoptosis) 和死亡，包括活性氧 (ROS) 产生、JNK 激活、线粒体膜去极化以及从线粒体释放 AIF。1D09C3 在 JVM-2 细胞和 GRANTA-519 细胞异种移植瘤小鼠模型中显示出强大的抗肿瘤活性，提高了总体生存率和中位生存期。1D09C3 可用于癌症研究，如慢性淋巴细胞白血病 (CLL)[1][2][3]。

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务

我们将采用定制合成服务的方式为您快速提供所需产品和技术服务

1D09C3 Chemical Structure

1D09C3 Chemical Structure

CAS No. : 791073-97-7

1.  客户无需承担相应的运输费用。

2.  同一机构（单位）同一产品试用装仅限申领一次，同一机构（单位）一年内

     可免费申领三个不同产品的试用装。

3.  试用装只面向终端客户。

规格 是否有货
1 mg   询价  
5 mg   询价  
10 mg   询价  

* Please select Quantity before adding items.

Customer Review

1D09C3 相关抗体

Top Publications Citing Use of Products

查看 MHC 亚型特异性产品:

查看所有亚型
MHC I

查看 JNK 亚型特异性产品:

查看所有亚型
JNK1 JNK2 JNK3 JNK

  • 生物活性

  • 纯度 & 产品资料

  • 参考文献

生物活性

1D09C3 is a fully human anti-HLA-DR monoclonal antibody. 1D09C3 induces apoptosis and cell death involving a cascade of events, including ROS generation, JNK activation, mitochondrial membrane depolarization, and AIF release from mitochondria. 1D09C3 shows potent anti-tumor activity and increases overall survival and median survival in JVM-2 cells and GRANTA-519 cells xenograft mice models. 1D09C3 can be used for the researches of cancer, such as chronic lymphocytic leukemia (CLL)[1][2][3].

IC50 & Target

HLA-DR β
体外研究
(In Vitro)

1D09C3 (2.5 µg/ mL, 24 h) 可显著减少 HLA-DR 阳性细胞系中的细胞计数并降低细胞存活率，但对 HLA-DR 阴性细胞系无此作用[1][2]。

1D09C3 (0.1-10 µg/ mL, 4-24 h) 可诱导 JVM-2 和 GRANTA-519 细胞出现强效的时间和剂量依赖性死亡[1]。

1D09C3 (10 µg/ mL, 4-24 h) 可通过非 caspase 依赖途径诱导 JVM-2 和 GRANTA-519 细胞凋亡[1]。

1D09C3 (10 µg/ mL, 5-240 min) 可诱导 JVM-2 和 GRANTA-519 细胞发生线粒体去极化并产生 ROS[1]。

1D09C3 (10 µg/ mL, 0.5-4 h) 可通过激活 JNK 诱导细胞死亡[1]。

1D09C3 (2.5 µg/ mL, 4 h) 可诱导 B-CLL 细胞死亡[1][3]。

1D09C3 (10 µg/ mL, 48 h) 可使活化的 T 细胞数量减少 20%，使静止和活化的 B 细胞数量减少 50%[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

1D09C3 相关抗体:

Cell Proliferation Assay[1]

Cell Line: HLA-DR+ cell lines JVM-2 and GRANTA-519 and the HLA-DR cell line SU-DHL-1
Concentration: 2.5 µg/ mL
Incubation Time: 24 h
Result: Reduced the absolute number of viable cells by 3-fold and 48-fold, and the survival of tumor cells by 33-fold and 25-fold for JVM-2 and GRANTA-519, respectively

Western Blot Analysis[1]

Cell Line: JVM-2 and GRANTA-519 cells
Concentration: 10 µg/mL
Incubation Time: 4, 18 and 24 h
Result: Showed no significant change of caspase-8, 9, 3 and RARP.

Western Blot Analysis[1]

Cell Line: GRANTA-519 cells
Concentration: 10 μg/mL
Incubation Time: 0.5, 1, 2 and 4 h
Result: Upregulated the levels of JNK in mitochondrial and AIF in cytosolic.
体内研究
(In Vivo)

1D09C3 (0.01-6 mg/mouse, 静脉注射) 显著提高了 JVM-2 细胞和 GRANTA-519 细胞异种移植瘤小鼠模型的总生存期和中位生存期[1]。

MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model: JVM-2 (1 x 106)cells xenograft mice models (NOD/SCID mice, 6-8 weeks)[1]
Dosage: 0.01 mg/mouse (day 4), 0.1 mg/mouse (day 4)
Administration: Intravenous injection
Result: Resulted in a 20% overall survival with a median survival time of 64 days.
Animal Model: JVM-2 (0.25 x 106) cells xenograft mice models (NOD/SCID mice, 6-8 weeks)[1]
Dosage: 3 x 1 mg/mouse (day 4, 7, 9) and 1 mg/mouse (day 4) for treatment of early-stage disease; 6 x 1 mg/mouse at 48-hour intervars starting onday 15 for treatment of advanced-stage disease
Administration: Intravenous injection
Result: Resulted in a 100% survival at dose up to 3 mg/mouse, and a 42% overall survival with a median survival of 99 days.
Animal Model: GRANTA-519 cells and KMS-11 cells xenograft mice models (NOD/SCID mice, 6-8 weeks)[1][2][3]
Dosage: 3 x 1 mg mouse (days 1, 4, and 7) for treatment of early-stage disease and 6 x 1 mg/mouse at 48-hour intervars starting onday 7 for treatment of advanced-stage disease
Administration: Intravenous injection
Result: Resulted in a significant increase of median survival (108 days), with 27% mice being alive and disease-free at the end of the 120-day observation period
应用

ELISA, FACS, Functional assay
偶联物

Unconjugated
复溶方法

The product can be reconstituted/diluted with sterile PBS or saline.
CAS 号
储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.
纯度 & 产品资料
参考文献

1D09C3 相关分类

  • 摩尔计算器

  • 稀释计算器

The molarity calculator equation

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

质量   浓度   体积   分子量 *
= × ×

The dilution calculator equation

Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

This equation is commonly abbreviated as: C1V1 = C2V2

浓度 (start) × 体积 (start) = 浓度 (final) × 体积 (final)
× = ×
C1   V1   C2   V2
Help & FAQs
  • Do most proteins show cross-species activity?

    Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

Keywords:

1D09C3791073-97-7MHCApoptosisJNKMajor Histocompatibility Complexc-Jun N-terminal kinaseHLA-DRCancerROSJNK,CLLInhibitorinhibitorinhibit

您最近查看的产品:

Your information is safe with us. * Required Fields.

   产品名称：

  

* 需求量：

* 客户姓名：

 

* Email：

* 电话：

 

* 公司或机构名称：

   留言给我们：

Bulk Inquiry

Inquiry Information

产品名称：
1D09C3
目录号：
HY-P991590
需求量：

Request for HNMR Report

Please fill out this form to request the QC report. We will send it to your Email address shortly.

Your information is safe with us. * Required Fields.

   产品名称：

  

* Lot #：

* 客户姓名：

 

* Email：

   电话：

 

* 部门：

* 公司或机构名称：

 

   留言给我们：

Request for HNMR Report

We have received your request and will respond to you as soon as possible.

嗨！很高兴为您提供帮助！

尊敬的 MCE 客户您好，
请您选择所在区域，我们将转接对应客服为您服务！

热门区域

A

B

C

F

G

H

J

L

N

Q

S

T

X

Y

Z

热 A B C F G H J L N Q S T X Y Z